Meta Biomed Selected for SME Ministry R&D Project... Accelerates Expansion of Biopolymer Materials Business

Meta Biomed has been selected for the Ministry of SMEs and Startups’ Research and Development (R&D) support program, accelerating the expansion of its biopolymer materials business. The company plans to leverage this project to strengthen its competitiveness in the high-performance medical materials sector and to establish a solid foundation for entry into global markets.

Meta Biomed announced that it was chosen as the lead research institution for the “Development of New Medical Materials” category within the “Global Leading Technology Development (Jump Up)” project, which is part of the Ministry of SMEs and Startups’ Technology Innovation Development Program for SMEs, and completed the agreement on April 15.

This program supports the development of strategic technologies and global collaboration, aiming to enhance technological competitiveness of small and medium-sized enterprises and expand their entry into global markets. Its purpose is to promote innovative growth among companies.

The company stated, “Through this project, we will further advance our proprietary medical polymer material synthesis technology and, based on this, build a materials platform applicable to a diverse range of biohealth product lines,” adding, “It is significant not only for enabling the supply of basic materials, but also for establishing a foundation to expand into applied products.”

Meta Biomed plans to secure high-value-added material supply technologies through this research, covering a spectrum from microparticles to implantable devices. In addition, the company will establish mass production technology to develop hybrid composite materials capable of high-load support for orthopedics, and will also promote the localization of high-value materials.

The company is restructuring its business portfolio around its Material Innovation Center, which was completed in 2025, focusing on new business areas including biodegradable polymer materials, polymer fillers, skin boosters, and beauty devices. Through these efforts, Meta Biomed aims to systematically build a foundation for mid- to long-term growth.

Previously, in October of last year, which marked its 35th anniversary, Meta Biomed announced “Vision 2030,” setting goals to achieve KRW 500 billion in sales and a corporate value of KRW 1 trillion by 2030. In particular, biodegradable polymer materials, which can be used in various sectors such as sutures and dermal fillers, are expected to play a key role in the company's future growth strategy.

This R&D support project will run for approximately two years, from April 2026 to March 2028, with KRW 1 billion in government funding included in a total R&D budget of KRW 1.6 billion.

Jisoo Oh, President of Meta Biomed, stated, “Through this R&D support project, we will further enhance the quality competitiveness of biodegradable polymer materials, establish a foundation for localization and global market entry, and continue to focus on increasing shareholder value alongside sustainable growth.”

This content was produced with the assistance of AI translation services.